Ask about this productRelated genes to: SCAMP1 Blocking Peptide
- Gene:
- SCAMP1 NIH gene
- Name:
- secretory carrier membrane protein 1
- Previous symbol:
- -
- Synonyms:
- SCAMP37
- Chromosome:
- 5q14.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-21
- Date modifiied:
- 2018-09-06
Related products to: SCAMP1 Blocking Peptide
Related articles to: SCAMP1 Blocking Peptide
- Sex-specific proteins are unique markers found on either X- or Y-chromosome bearing spermatozoa, acting like molecular signatures, and can be used as a key target to distinguish X- or Y-bearing cells. Towards this goal, by reviewing the literature, a total of 6 proteins were selected from the selected, of which 2, CLRN3 and SCAMP1, were finally chosen for the immunoprecipitation study. For the finally selected proteins, predictions of subcellular localisation and transmembrane topology were generated using online tools such as BUSCA, DeepLoc 2.0, DeepTMHMM, and TMHMM. Additionally, several online platforms like SEMMA 2.0 and IEDB were employed to identify potential immunogenic targets. Following this, commercially available antibodies against the 2 identified proteins were procured for subsequent use in multiple immunoprecipitation-based techniques, such as Western blotting, immunocytochemistry, and ELISA (Enzyme-linked immunosorbent assay). Targeting these proteins revealed their binding intensity on spermatozoa. In this study, the CLRN3 antibody targeting X-spermatozoa showed stronger interaction with X-sorted samples than the Y-specific SCAMP1 antibody in the cell-based ELISA. Results from the study suggest targeting sex-specific surface proteins could enable the development of an immune-based sperm-sorting technique in bovines. Overall, the results support the potential of CLRN3 as an X-specific surface marker that needs further validation for the development of a novel immune-based sperm sorting technique. - Source: PubMed
Debnath AshmitaPundla Hemanth KumarDeshmukh KaivalyaPandey Vineet KumarSrivastava NeerajKumar AjayIrungbam KarunaGhosh Subrata KumarSingh S KKumar MukeshLakshminarayanan SujathaPrakash BhanuSingh Praveen - BACKGROUND: Curebest™ 95GC breast is a multigene assay independently developed in Japan, that utilizes DNA microarray technology to analyze the expression patterns of the 95 genes in breast cancer tissue. It calculates a 95GC score and classifies postoperative recurrence risk into two categories: Low and High. This study aimed to evaluate whether the 95GC score can also be calculated using RNA sequencing (RNAseq), and to assess the clinical utility of mutational profiles derived from RNAseq data. METHODS: To transition the 95GC scoring method from microarray to RNAseq, we analyzed a total of 151 breast cancer cases, comprising a training set of 34 cases and a validation set of 117 cases. Whole RNAseq was performed using residual RNA samples after microarray analysis. The 95GC scores calculated from RNAseq were compared with those from microarray, and comprehensive mutation profiling was conducted. RESULTS: The correlation coefficients between the 95GC score (microarray) and the 95GC score (RNAseq) were high in both the training set (R = 0.96, R² = 0.93) and the validation set (R = 0.95, R² = 0.90). Comprehensive mutation analysis identified eight frequently mutated genes (each mutated in > 10% of cases): SCAMP1 (66%), FLNB (61%), TTN (40%), BLCAP (31%), FLNA (25%), PIK3CA (18%), CDK13 (11%), and OBSCN (10%). Furthermore, it was feasible to analyze mutations in the 309 genes included in the FoundationOne®CDx panel and the 124 genes included in the OncoGuide™ NCC Oncopanel System. CONCLUSIONS: This study demonstrates the potential of RNAseq-based analysis to enable both recurrence risk prediction and companion diagnostics for treatment selection in breast cancer, suggesting a novel direction for the development of next-generation multigene assays. Further accumulation of cases is warranted to evaluate the concordance of mutation profiles between DNAseq and RNAseq in breast cancer-related genes. - Source: PubMed
Publication date: 2026/04/01
Kato ChikageSota YoshiakiKitano SaeWatanabe AkiraNishida MaikoMotonari DaithoSaito YuriaKobayashi MasakiMorita MidoriSakaguchi KoichiShimazu KenzoNaoi Yasuto - BACKGROUND: TCOF1 is a nucleolar protein involved in ribosome biogenesis, DNA damage response, and mitotic regulation. Germline TCOF1 mutations are associated with Treacher-Collins syndrome, a rare congenital disorder characterized by craniofacial abnormalities. Clear cell renal cell carcinoma (ccRCC), the most prevalent form of kidney cancer, exhibits pronounced nuclear and nucleolar pleomorphism, which correlates with tumour aggressiveness. The ccRCC grading system relies on microscopic evaluation of nuclear and nucleolar features. Here, we hypothesized that TCOF1 contributes to ccRCC tumorigenesis. METHODS: The study involved 200 tissue samples from ccRCC patients, two ccRCC-derived cell lines, and the publicly available cancer datasets. The used techniques included siRNA transfections, proliferation, viability, migration, and adhesion assays, proteomic and transcriptomic analyses, Western blot, real-time PCR, and angiogenesis evaluation using HUVEC cells. RESULTS: TCOF1 expression was elevated in ccRCC tumours and correlated with higher nucleolar grade and poorer patient survival. TCOF1 depletion altered the expression of multiple genes and proteins involved in the Golgi secretory pathway, including AVL9, GOLGA4, GOPC, RPS6KA5, SCAMP1, SEC24B, and STEAP3. These changes led to enhanced secretion of the anti-angiogenic thrombospondin 1 and suppression of angiogenesis. Furthermore, TCOF1 silencing downregulated several proteins implicated in craniofacial development, such as DCAF7 (aka WDR68), CHUK, APAF1, DICER1, and ETS1. CONCLUSIONS: To our knowledge, this is the first study linking a nucleolar TCOF1 protein to the regulation of cellular secretion. Our findings suggest that elevated TCOF1 expression may disrupt the Golgi secretory pathway, inhibit thrombospondin 1 secretion, and promote angiogenesis in ccRCC. Our study also contributes to the understanding of the molecular consequences of TCOF1 dysfunction in Treacher-Collins syndrome. - Source: PubMed
Publication date: 2026/03/17
Grzanka MałgorzataPopławski PiotrWiśniewski Jacek RIwanicka-Nowicka RoksanaKossowska HelenaKoblowska MartaRybicka BeataBiałas AlexPiekiełko-Witkowska Agnieszka - Long non-coding RNAs (lncRNA) participate in regulation of gene expression and biology manipulation and altered lncRNA expression associated with cancer development and progression. The lncRNA SCAMP1 expression was aberrant and changed various cancer malignant behaviors. This study assessed SCAMP1 expression in pancreatic ductal adenocarcinoma (PDAC) for association with clinicopathological parameters and survival of patients and then explored the underlying molecular events. The data revealed that SCAMP1 expression was significantly upregulated in PDAC tissues, which was associated with a larger tumor size and tumor de-differentiation as well as poor survival of patients. Knockdown of SCAMP1 expression reduced tumor cell growth, invasion, epithelial‑mesenchymal transition (EMT), and improved sensitivity to 5-fluorouracil (5-FU) in vitro and inhibited tumor cell xenograft growth in nude mice. At gene levels, SCAMP1 was able to target miR-106a-5p to in turn upregulate acylglycerol kinase (AGK) expression and promote PDAC malignant behaviors in vitro. The data from the current study demonstrated an oncogenic SCAMP1 activity in PDAC. Further study will investigate SCAMP1 as a tumor biomarker and novel target in control of PDAC clinically. - Source: PubMed
Publication date: 2025/11/18
Du XiyaoCai YunlongKuang PengZeng MoHuang YingliHuang Shanshan - Exosomes are extracellular vesicles that facilitate communication among cells by exchanging signaling biomolecules with adjacent cells. Among the diverse signaling biomolecules, long noncoding RNAs (lncRNAs) can be selectively packaged into exosomes to influence cancer onset and progression through various mechanisms. This study aimed to explore the role of exosomal lncRNA SCAMP1-AS1 in osteosarcoma (OS). The expression of SCAMP1-AS1 was determined by quantitative reverse-transcription polymerase chain reaction in OS samples, and its role in OS was investigated by performing Cell Counting Kit-8, EdU, and Transwell assays. The characterization of exosomes derived from OS cell lines was conducted by transmission electron microscopyand Western blotting of CD9 and CD81. The effects of exosomes and exosomal SCAMP1-AS1 on OS cells were also evaluated in a series of cell assays. Furthermore, key molecules in the liver kinase B1-adenosine monophosphate-activated protein kinase (LKB1-AMPK) signaling pathway were analyzed by through Western blotting. The results revealed high SCAMP1-AS1 expression in OS, and its silencing in OS cells led to a reduction in cell proliferation, migration, and invasion. The OS cell-derived-exosomes increased the malignant characteristics in the target OS cell lines. Notably, exosomes obtained from OS cells in which SCAMP1-AS1 was silenced effectively counteracted the tumor-promoting effects typically observed with OS-derived exosomes on cocultured target OS cells by activating the LKB1-AMPK signaling pathway. These results demonstrate that exosomal SCAMP1-AS1 serves as a tumor promoter in OS by regulating the LKB1-AMPK signaling pathway. - Source: PubMed
Publication date: 2025/08/12
Li YanxiaZou XiuqiFeng XiaominXia JingWu ZhifengMa Haili